TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9692119
Drug: Prednisolone 0.5
Normalized name: prednisoLONE 0.5 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.5 mg kg-1
Study: 9692119
Drug: Prednisolone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1.0 mg kg-1
Study: 9692119
Drug: Prednisolone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 2.0 mg kg-1
Study: 7921938
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin at a concentration of 1 mg/ml (n = 40)
Study: 7921938
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin at a concentration of 2 mg/ml (n = 41)
Study: 2908134
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg bromazepam
Study: 27838660
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine inhaler
Study: 27838660
Drug: nicotine administration
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotine administration
Study: 24347903
Drug: Hybrid fractionation
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid fractionation (6GyX3 fractions on alternate days during the 1st week, followed by 2GyX5 daily fractions in the 2nd week)
Study: 24347903
Drug: Standard fractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fractionation (3GyX5 daily fractions for 2 consecutive weeks)
Study: 16473752
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 2 weeks)
Study: 10695943
Drug: Intraoral fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral fluoride releasing device (IFRD) consisting of sodium fluoride encased in an acrylic polymer, releasing fluoride at approximately 0.04 mg/day
Study: 9085402
Drug: Buprenorphine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4, 8, 16 mg)
Study: 9085402
Drug: Hydromorphone (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (9 and 18 mg)
Study: 8335191
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg body weight) combined with prednisolone (60 mg daily tapering to 10 mg)
Study: 8335191
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg daily tapering to 10 mg) monotherapy
Study: 8335191
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg body weight) combined with prednisolone
Study: 30049743
Drug: Prednisolone monotherapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone monotherapy
Study: 24525661
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 (4 to 8 mg twice daily)
Study: 24525661
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 (12 to 16 mg twice daily)
Study: 20162706
Drug: Intravesical gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical gemcitabine (2000 mg/50 mL) twice weekly for 6 weeks, then weekly for 3 weeks at 3, 6, and 12 months
Study: 20162706
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6-week induction course and weekly for 3 weeks at 3, 6, and 12 months
Study: 15917336
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 1200 mg daily
Study: 14699228
Drug: Pyridostigmine continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine continued with morning dose on the day of surgery (Group 2)
Study: 10805066
Drug: Gavestinel 800
Normalized name: Gavestinel
DrugBank: Gavestinel (DB06741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gavestinel 800 mg loading dose followed by 100-, 200-, or 400-mg maintenance doses every 12 hours for five doses
Study: 7963447
Drug: Dothiepin 75-150
Normalized name: dothiepin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin 75-150 mg/day
Study: 3308579
Drug: Buffy coat
Normalized name: Leucocyte buffy coat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffy coat transfusions (approximately 0.6 X 10(9) T-lymphocytes) weekly for 5 weeks
Study: 24763133
Drug: Vedolizumab 750
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab 750 mg
Study: 23865726
Drug: Fluticasone propionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/formoterol (flutiform) 250/10 µg b.i.d.
Study: 22352202
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) therapy added to NIAAA protocol for 2004
Study: 19043252
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB; amlodipine or nifedipine)
Study: 2550642
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily with hydrochlorothiazide 25 mg
Study: 2550642
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg once daily with hydrochlorothiazide 25 mg
Study: 16672214
Drug: Molocco+B12 tablets
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molocco+B12 tablets
Study: 15610110
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg (with option to titrate to 5, 10, or 20 mg)
Study: 11377409
Drug: Naltrexone (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (started at 25 mg/day, titrated up to 250 mg/day)
Study: 30406565
Drug: Anti-citrullinated α-enolase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1)
Study: 30406565
Drug: Anti-mutated citrullinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-mutated citrullinated vimentin antibodies (a-Sa)
Study: 30406565
Drug: Anti-caramylated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-caramylated protein antibodies (a-CarP)
Study: 30406565
Drug: Anti-hnRNP/RA33 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hnRNP/RA33 antibodies (a-hnRNP/RA33)
Study: 30406565
Drug: Anti-filaggrin antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-filaggrin antibodies (AFAs)
Study: 26632177
Drug: 0.5% Rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Rice Bran Supercritical CO2 Extract (RB-SCE) applied dermally (8 mL/d) for 16 weeks
Study: 23277250
Drug: Iloperidone 8
Normalized name: iloperidone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 8 mg BID
Study: 23277250
Drug: Iloperidone 12
Normalized name: iloperidone 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 12 mg BID
Study: 23277250
Drug: Iloperidone 24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 24 mg QD
Study: 23277250
Drug: Quetiapine 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 375 mg BID
Study: 23277250
Drug: Iloperidone with
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone with metabolic inhibitors (paroxetine and ketoconazole)
Study: 10934078
Drug: Ciprofloxacin monotherapy
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin monotherapy with reevaluation at 3 days
Study: 10934078
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (choice and duration of antibiotics at the discretion of physicians)
Study: 10934078
Drug: Ciprofloxacin monotherapy
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin monotherapy
Study: 8681595
Drug: Pentoxifylline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1.5 mg/kg/hr iv) for 5 days in trauma patients (n = 15)
Study: 8681595
Drug: Pentoxifylline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1.5 mg/kg/hr iv) for 5 days in sepsis patients (n = 15)
Study: 8681595
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo in trauma patients (n = 15)
Study: 8681595
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo in sepsis patients (n = 15)
Study: 1558329
Drug: mPEG modified
Normalized name: MPEG 6000 acetyl lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mPEG modified grass pollen mix allergen preparation (mPEG‐gm)
Study: 1558329
Drug: Partly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partly purified grass pollen mix allergen preparation (gm)
Study: 1558329
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments at high dose levels (120,000 BU)
Study: 6395323
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (Cyklocapron, 4.5 g per day for 6 weeks)
Study: 31433269
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3000 mg/day, 1053 mg omega-3 fatty acids) plus wheat germ oil (300 mg/day, 0.765 mg vitamin E)
Study: 11179277
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine
Study: 11179277
Drug: Oral homocysteine
Normalized name: mecysteine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral homocysteine
Study: 2963746
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (300 mg/day) medroxyprogesterone acetate
Study: 2963746
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1000 mg/day) medroxyprogesterone acetate
Study: 28545189
Drug: Modified Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Triple Therapy (MTT): 20 mg omeprazole t.i.d., 500 mg amoxicillin t.i.d., and 500 mg clarithromycin b.i.d. for 14 days
Study: 28545189
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triple Therapy (STT): 20 mg omeprazole b.i.d., 1000 mg amoxicillin b.i.d., and 500 mg clarithromycin b.i.d. for 14 days
Study: 17878149
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg yearly intravenous infusion)
Study: 9129487
Drug: Psyllium (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (1.4 g/MJ)
Study: 2885462
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone for 7 days added to antibiotic regimen
Study: 30246186
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants with a temporary resin fixed partial denture
Study: 30246186
Drug: Conventionally loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally loaded implants with definitive multi-unit abutments
Study: 26949133
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment alone)
Study: 26201510
Drug: Weekly supervised
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supervised group sessions of progressive balance training for two years, supplemented by individually prescribed home exercises
Study: 26201510
Drug: Weekly supervised
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supervised group sessions of progressive balance training for two years
Study: 18938022
Drug: Caries Check
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries Check (CC)
Study: 16675163
Drug: Outreach Case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outreach Case Management (OCM) for 6 weeks, designed to motivate and coach patients to re-enter treatment.
Study: 16675163
Drug: Passive Referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Referral (PR) for drug treatment, n=52.
Study: 3729666
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride 0.1 mg/kg
Study: 3729666
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride 2.0 mg/kg
Study: 31643142
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (case manager and doctor)
Study: 29105893
Drug: Conventional meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional meal (potato-cheese cream followed by vanilla cream)
Study: 29105893
Drug: Unconventional meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconventional meal (mixture of both creams)
Study: 15932835
Drug: Bazedoxifene 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 10 mg/d
Study: 12796576
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg oxandrolone twice a day (n = 14)
Study: 12796576
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg oxandrolone
Study: 12634875
Drug: beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker therapy (bisoprolol, carvedilol, metoprolol)
Study: 6476789
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dose of pyridoxine hydrochloride
Study: 30379814
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pentamidine isethionate (PI) 7 mg/kg
Study: 30379814
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of pentamidine isethionate (PI) 7 mg/kg
Study: 30379814
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of pentamidine isethionate (PI) 7 mg/kg
Study: 23514685
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection technique
Study: 17689509
Drug: Intracoronary BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracoronary BH4 (250 microg/min & 500 microg/min) co-administered with acetylcholine (Ach, 10(‐7) & 10(‐6) M)
Study: 17689509
Drug: Intracoronary BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracoronary BH4 (500 microg/min) co-administered with acetylcholine (Ach, 10(‐7) & 10(‐6) M)
Study: 17689509
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BH4 treatment)
Study: 16248952
Drug: Tumor vaccine
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor vaccine (3 vaccinations at 2-week intervals, consisting of formalin-fixed HCC tissue fragments, biodegradable sustained-releasers of GM-CSF, IL-2, and an adjuvant)
Study: 11895628
Drug: Threshold doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold doses for allergenic foods
Study: 7766742
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.), Metronidazole (400 mg t.d.s.) for 14 days
Study: 7766742
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.), Metronidazole (400 mg t.d.s.) for 7 days
Study: 7766742
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.) for 7 days and Metronidazole for 5 days
Study: 26899778
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg orally on days 1-21 every 28 days)
Study: 26899778
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice monotherapy (rituximab, gemcitabine, fludarabine, chlorambucil, or cytarabine)
Study: 19776140
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g prebiotics/d
Study: 19776140
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g dextrin maltose/d
Study: 2520624
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of 40 mg famotidine
Study: 2520624
Drug: Bedtime dose
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dose of 40 mg famotidine
Study: 2520624
Drug: Both morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morning and bedtime doses of famotidine
Study: 4741605
Drug: Mestranol, average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mestranol, average daily dose of 23 mug, started within two months of operation
Study: 4741605
Drug: Mestranol, average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mestranol, average daily dose of 23 mug, started three years after oophorectomy
Study: 4741605
Drug: Mestranol, average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mestranol, average daily dose of 23 mug, started six years after oophorectomy
Study: 16533356
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day) and zinc sulphate (66 mg/day)
Study: 12713766
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus pravastatin (pooled doses)
Study: 12713766
Drug: Pravastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin alone (pooled doses)
Study: 10982248
Drug: rhEPO 200
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sucrose 200 mg intravenously twice weekly
Study: 10982248
Drug: rhEPO 200
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sulfate 160 mg/day orally
Study: 29925680
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Treatment (NPT) applied on the sutured wound for one week postoperatively
Study: 27255080
Drug: Medication-adherence tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-adherence tool intervention
Study: 27255080
Drug: Medication-adherence assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-adherence assessment (Control)
Study: 19661244
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg/d
Study: 16451406
Drug: Piperacillin-tazobactam monotherapy
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam monotherapy
Study: 11318079
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily with azithromycin
Study: 11318079
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg twice daily with azithromycin
Study: 2835890
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg once daily
Study: 21044669
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of PCV-7
Study: 21044669
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of PCV-7
Study: 21044669
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of PCV-7
Study: 21044669
Drug: 0 doses
Normalized name: mometasone furoate 220 mcg/actuation (30 doses) INHALATION AEROSOL POWDER, BREATH ACTIVATED (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 doses of PCV-7 (unvaccinated group)
Study: 18789766
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (44 mcg subcutaneous three times per week)
Study: 18789766
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (20 mg subcutaneous once per day)
Study: 29019365
Drug: Blueberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry supplementation (22.5 g freeze-dried) twice daily for six weeks
Study: 23506636
Drug: Carvedilol (25.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25.6 ± 12.6 mg daily)
Study: 23506636
Drug: Bisoprolol (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5.0 ± 2.4 mg daily)
Study: 23506636
Drug: Nebivolol (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5.0 ± 2.4 mg daily)
Study: 15602250
Drug: Ice application
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice application before injections
Study: 3659227
Drug: H1-antagonist dimethindene
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-antagonist dimethindene (Di) (0.1 mg/kg i.v.)
Study: 3659227
Drug: H2-antagonist cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2-antagonist cimetidine (Ci) (5 mg/kg i.v.)
Study: 3659227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimethindene and cimetidine (Di + Ci)